

Company name: KYORIN Holdings, Inc.  
Representative: Masahiro Yamashita  
Representative Director, President  
(Securities Code: 4569, TSE 1st Sec.)

**Launch of “AIPHAGAN<sup>®</sup> Ophthalmic Solution 0.1%”**

**for the treatment of Glaucoma / Ocular Hypertension, in Japan**

**TOKYO, Japan (April 20, 2012)** — Senju Pharmaceutical Co., Ltd. (Head office: Chuo-ku, Osaka, President: Yukoh Yoshida) will launch AIPHAGAN<sup>®</sup> Ophthalmic Solution 0.1% (Generic name: brimonidine tartrate) on May 11, 2012, which KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President: Keiji Hirai), a wholly owned subsidiary of KYORIN Holdings, Inc., licensed from a US based multi-specialty health care company, Allergan, Inc. and sublicensed to Senju Pharmaceutical in 2004.

“AIPHAGAN<sup>®</sup> Ophthalmic Solution 0.1%” is a quid quo pro product for gatifloxacin ophthalmic solution (Brand name by Allergan: Zymaxid<sup>®</sup> or Zymar<sup>®</sup>) that was licensed by Kyorin Pharmaceutical to Allergan in August 2000.

Brimonidine tartrate is a novel intraocular pressure (IOP) lowering drug developed by Allergan that shows high selectivity for  $\alpha_2$ -adrenergic receptor; while regulating aqueous humor production, it promotes aqueous humor outflow via uveoscleral pathway, exhibiting IOP lowering effect. In 1996, this brimonidine tartrate ophthalmic solution was approved for the indication for "open-angle glaucoma or ocular hypertension" in the United States, and it is currently approved in 84 countries and areas including the U.S. and is widely used in clinical sites (as of September 2011).

In clinical studies conducted in Japan, "AIPHAGAN<sup>®</sup> Ophthalmic Solution 0.1%" approved this time exhibited long-term stable IOP lowering effect for primary open-angle glaucoma (broad definition) as a single drug or in combination with other therapeutic drugs for glaucoma.

Glaucoma is "a disease that is characterized by ocular functional structural abnormality where optic nerve neuropathy can be normally improved or controlled by sufficient IOP reduction, with characteristic changes in optic nerve and visual field." Therefore, IOP reduction is the only evidence-based treatment method; as the lost visual field cannot be recovered, it is viewed important to continue to control IOP for entire lifetime. Thus, in selecting drugs, what is desired is an ophthalmic solution that has sufficient IOP-lowering effect and is highly sustainable and safe.

Kyorin Group has a corporate philosophy that it contributes to the better health of people around the world and expects that “AIPHAGAN<sup>®</sup> Ophthalmic Solution 0.1%” will contribute to the enhancement in quality of life for the patients as well as the ophthalmological medical care in Japan.

KYORIN Pharmaceutical will receive sales related royalties from Senju Pharmaceutical.

## **Overview of AIPHAGAN<sup>®</sup> Ophthalmic Solution 0.1%**

Product name:	"AIPHAGAN <sup>®</sup> Ophthalmic Solution 0.1%" (Brimonidine Tartrate)
Therapeutic category:	Therapeutic agent for glaucoma, ocular hypertension
Indication:	When the other glaucoma therapeutic agents are not effective enough or cannot be used in the following diseases: Glaucoma, ocular hypertension
Dosage and administration	Instillation of one drop twice daily normally.
Date of approval:	January 18, 2012
Date of NIH drug listing:	April 17, 2012
Drug Price:	AIPHAGAN <sup>®</sup> Ophthalmic Solution 0.1% : 438.20Yen for 1 mL